A Phase II clinical trial examined the synergistic effects of ISA101 in combination with the programmed cell death protein 1 (PD-1) inhibitor nivolumab in 26 individuals diagnosed with advanced HPV-positive oropharyngeal carcinoma. Here, PDCD1 is linked to oropharyngeal carcinoma.